Mycobacterium Avium-Intracellulare Infections - Pipeline Review, H2 2012

Global Markets Direct, July 2012, Pages: 39

Mycobacterium Avium-Intracellulare Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Mycobacterium Avium-Intracellulare Infections - Pipeline Review, H2 2012', provides an overview of the Mycobacterium Avium-Intracellulare Infections therapeutic pipeline. This report provides information on the therapeutic development for Mycobacterium Avium-Intracellulare Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mycobacterium Avium-Intracellulare Infections. 'Mycobacterium Avium-Intracellulare Infections - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Mycobacterium Avium-Intracellulare Infections.
- A review of the Mycobacterium Avium-Intracellulare Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Mycobacterium Avium-Intracellulare Infections pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Mycobacterium Avium-Intracellulare Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Mycobacterium Avium-Intracellulare Infections pipeline depth and focus of Mycobacterium Avium-Intracellulare Infections therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Mycobacterium Avium-Intracellulare Infections Therapeutic Products under Development, Key Players in Mycobacterium Avium-Intracellulare Infections Therapeutics, Mycobacterium Avium-Intracellulare Infections Pipeline Overview, Mycobacterium Avium-Intracellulare Infections Pipeline, Mycobacterium Avium-Intracellulare Infections Pipeline Assessment

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Mycobacterium Avium-Intracellulare Infections Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Mycobacterium Avium-Intracellulare Infections 7
Mycobacterium Avium-Intracellulare Infections Therapeutics under Development by Companies 9
Mycobacterium Avium-Intracellulare Infections Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Mycobacterium Avium-Intracellulare Infections Therapeutics – Products under Development by Companies 14
Mycobacterium Avium-Intracellulare Infections Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Mycobacterium Avium-Intracellulare Infections Therapeutics Development 16
Mycobacterium Avium-Intracellulare Infections – Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Combination Products 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Drug Profiles 22
Clarithromycin + Ethambutol + Rifabutin - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Clarithromycin + Ethambutol + Clofazimine - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Amithiozone + Clarithromycin + Ethambutol + Rifampin + Streptomycin - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Actimmune + Leukine - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Rifampicin - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
RHB-104 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
RHB-104 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Mycobacterium Avium-Intracellulare Infections Therapeutics – Drug Profile Updates 33
Mycobacterium Avium-Intracellulare Infections Therapeutics - Dormant Products 34
Mycobacterium Avium-Intracellulare Infections – Product Development Milestones 35
Featured News & Press Releases 35
Jun 28, 2007: ZIOPHARM Presents ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data At International Myeloma Workshop 35
Dec 14, 1995: FDA Advisory Committees Recommend Marketing Approval Of Biaxin 36
Dec 27, 1994: Abbott Laboratories submits Supplemental NDA for Biaxin 36
Aug 25, 1992: Abbott Files New Drug Application For Pediatric Antibiotic 36
Nov 01, 1991: Abbott Introduces New Macrolide Antibiotic In U.S. 36
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 39
Disclaimer 39

List of Tables
Number of Products Under Development for Mycobacterium Avium-Intracellulare Infections, H2 2012 7
Products under Development for Mycobacterium Avium-Intracellulare Infections – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Assessment by Monotherapy Products, H2 2012 16
Assessment by Combination Products, H2 2012 17
Assessment by Stage and Route of Administration, H2 2012 19
Assessment by Stage and Molecule Type, H2 2012 21
Mycobacterium Avium-Intracellulare Infections Therapeutics – Drug Profile Updates 33
Mycobacterium Avium-Intracellulare Infections Therapeutics – Dormant Products 34

List of Figures
Number of Products under Development for Mycobacterium Avium-Intracellulare Infections, H2 2012 7
Products under Development for Mycobacterium Avium-Intracellulare Infections – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 16
Assessment by Combination Products, H2 2012 17
Assessment by Route of Administration, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 19
Assessment by Molecule Type, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 21

Customers who bought this item also bought

• Mycobacterium Infections - Pipeline Review, H2 2012
• Fungal Infections - Pipeline Review, H2 2012
• Other Viral Infections - Pipeline Review, H2 2012
• Urinary Tract Infections - Pipeline Review, H2 2012
• Rotavirus Infections - Pipeline Review, H2 2012
• Bacterial Respiratory Tract Infections - Pipeline Review, H2 2012
• Influenza A Infections - Pipeline Review, H2 2012
• Clostridium Botulinum Infections - Pipeline Review, H2 2012
• Other Bacterial Infections - Pipeline Review, H2 2012
• Infections Caused By Picornaviridae - Pipeline Review, H2 2012